Avai Bio, Inc. filed a Form 10-Q with the SEC on November 13, 2026, covering the quarterly period ended September 30, 2026, disclosing continued operating losses, zero revenue, and a growing stockholders' deficit.

Key Highlights

  • No revenue: The company reported $0 in revenue for both the three and six months ended September 30, 2026, according to the filing.
  • Net loss of $805,281: The net loss for the six months ended September 30, 2026 was $805,281, compared to $940,605 for the same period in 2025.
  • Stockholders' deficit widened: Total stockholders' deficit reached $(3,415,806) as of September 30, 2026, up from $(2,815,155) as of March 31, 2026.
  • Total liabilities of $4,534,882: Current liabilities included accounts payable of $1,894,634, convertible notes payable of $528,657, loan payable to related parties of $1,355,306, and loan payable of $756,285.
  • Accumulated deficit of $6,673,300: The accumulated deficit grew from $5,868,019 at March 31, 2026 to $6,673,300 at September 30, 2026.
  • 154,872,536 shares outstanding: Common shares issued and outstanding as of November 13, 2026 totaled 154,872,536, per the filing.
  • Accounts payable converted to shares: During the six months ended September 30, 2026, the company converted accounts payable into 1,144,315 common shares in two separate transactions totaling $204,630 in value.

Avai Bio Financial Results for the Quarter and Six Months Ended September 30, 2026

Avai Bio, Inc. (OTC:AVAI), formerly known as Avant Technologies Inc. and previously as Trend Innovations Holding Inc., disclosed financial results for the three and six months ended September 30, 2026 in a 10-Q filed on November 13, 2026. According to the filing, the company generated no revenue in either period reported, and total operating expenses for the six-month period were $673,023, compared to $882,255 for the same period in the prior year. Operating expense components for the six months ended September 30, 2026 included general and administrative expenses of $350,784, consulting services of $165,000, marketing expenses of $101,670, professional fees of $41,717, amortization expense of $13,852, and no research and development expenses.

Beyond operating expenses, the filing reported other expenses for the six months ended September 30, 2026 including a discount on convertible notes of $47,100, net interest expense of $60,615, and a loss on disposal of a subsidiary of $24,543. These items contributed to a net loss of $805,281 for the six-month period. For the three months ended September 30, 2026 alone, the net loss was $253,240, compared to $453,016 for the same quarter in 2025.

As of September 30, 2026, the company reported total assets of $1,119,076, up from $572,696 as of March 31, 2026, with cash and cash equivalents of $121,948. Total liabilities stood at $4,534,882, resulting in a total stockholders' deficit of $(3,415,806). The company is incorporated in Nevada and classified itself as a non-accelerated filer and smaller reporting company. The filing states that the company is not a shell company. Common stock is authorized at 500,000,000 shares with a par value of $0.001.

What Was Disclosed

Avai Bio, Inc. filed a quarterly report disclosing zero revenue, a net loss of $805,281 for the six months ended September 30, 2026, a stockholders' deficit of $(3,415,806), accumulated deficit of $6,673,300, and total liabilities of $4,534,882 as of September 30, 2026.